Ofweek Medical News has achieved brilliant results in the first three quarters, with gross profit margin and net interest rate rising simultaneously: The company released the third quarterly report for 2016. In the first three quarters of 2016, the company achieved operating income of 1.449 billion yuan, up 28.25% year-on-year, and net profit of 84.7 million yuan. , a year-on-year increase of 37.92%. Among them, the company achieved operating income of 551 million yuan in the third quarter of 2016, a year-on-year increase of 32.68%, and a net profit of 36.19 million yuan, a year-on-year increase of 38.71%. The company achieved a substantial increase in its performance in the third quarter, mainly due to:
(1) The company's gross profit margin and net profit margin increased year-on-year. The company's single quarter gross profit margins for the first quarter, second quarter and third quarter of 2016 were 24.92%, 26.37% and 28.72%, respectively, corresponding to a net interest rate of 4.37%. , 6.95% and 7.12%.
(2) Yidan Bio and Xinhai Runbang, which the company acquired this year, began to consolidate in the third quarter of this year, contributing a certain amount of performance to the company.
In-depth expansion of product channels, integrated service business platform to the country: In the near future, the company's actions continue, further deepen product channels. In July this year, it acquired 45% equity of Yidan Bio (Zhejiang Market), acquired 100% equity of Xinhai Runbang in August (Shandong area), reached strategic cooperation with Jin Zerui in September (Northeast Market), and acquired Modi Medical 20% in October. Equity (Fujian area). We believe that more cooperation and mergers and acquisitions are expected in the future. At the same time, the company has provided comprehensive services for hospital customers since 2010. In recent years, the overall integrated service business has developed rapidly and its scale has gradually expanded. At present, the company has provided comprehensive services to nearly 150 customers, located in Shanghai, Jiangsu, Anhui, Shandong, Heilongjiang, Hebei, Yunnan, Tianjin, Inner Mongolia, Hubei, etc. The company has begun to move from regional enterprises in the former East China region. The transformation of national enterprises will gradually build a nationwide overall integrated service business platform.
The industrial chain extends vertically and the value of the platform is deeply explored: As an IVD integrated service provider, the company is actively expanding its upstream and downstream business by leveraging its own advantages. In the upstream aspect, the company's IVD products are gradually enriched. The self-produced products include hundreds of product specifications including glycated hemoglobin analyzer and supporting reagents, blood gas analyzer and supporting reagents and various biochemical reagents. At the same time, the products are further enriched through investment and acquisition, and the capital is increased. Runnuos, deep research and development of chemiluminescence reagents; strategic investment in Wuhan Haijili, improve molecular diagnostic layout; acquire 43.1% stake in RBM, enter POCT field; acquire 20% stake in McGrady Medical, expand early tumor screening and telemedicine diagnosis market. Downstream, it began to engage in third-party inspection services. In September 2015, the company cooperated with Guangzhou Jinyu to establish Shanghai Runjin Medical Technology Co., Ltd. to jointly carry out medical laboratory comprehensive services and regional medical inspection service platforms; 2016 4 In the month, the company and the four top three hospitals in Heilongjiang Province signed the "Cooperation Agreement" to jointly build a clinical medical precision testing and testing center. We believe that the vertical extension of the company's industrial chain is expected to bring new growth points to the company's performance.
Investment suggestion: We forecast that the company's earnings per share from 2016 to 2018 will be 0.48, 0.64 and 0.78 yuan respectively, and we will give an increase of one A. The 6-month target price is 36 yuan, which is equivalent to the dynamic P/E ratio of 75 times in 2016.
Our super green powder are mainly used as food supplement, health and wellness product additive, you can mix the super greens and Vegetable Powder according to your own formula. Spirulina, chlorella, broccoli powder, kale powder, buckwheat powder, wheatgrass powder, barley grass powder. Those powders are rich in protein, fibers, antioxidant and chlorophyll which can clear free radicals, enhance immunity and providing trace elements people can`t obtain from high carbohydrate diet. Organic super greens powders are Non-GMO, gluten free and vegan friendly, welcome to reach us for more you would like to know.
Super Greens,Buckwheat Grass,Organic Super Greens,Super Greens Powder
YT(Xi'an) Biochem Co., Ltd. , https://www.ytnutra.com